Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study.


Journal

American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369

Informations de publication

Date de publication:
02 2023
Historique:
revised: 10 10 2022
received: 05 04 2022
accepted: 24 10 2022
pubmed: 3 1 2023
medline: 13 1 2023
entrez: 2 1 2023
Statut: ppublish

Résumé

Familial forms of monoclonal gammopathy, defined as multiple myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS), are relatively infrequent and most series reported in the literature describe a limited number of families. MM rarely occurs in a familial context. MGUS is observed much more commonly, which can in some cases evolve toward full-blown MM. Although recurrent cytogenetic abnormalities have been described in tumor cells of sporadic cases of MM, the pathogenesis of familial MM remains largely unexplained. In order to identify genetic factors predisposing to familial monoclonal gammopathy, the Intergroupe Francophone du Myélome identified 318 families with at least two confirmed cases of monoclonal gammopathy. There were 169 families with parent/child pairs and 164 families with cases in at least two siblings, compatible with an autosomal transmission. These familial cases were compared with sporadic cases who were matched for age at diagnosis, sex and immunoglobulin isotype, with 10 sporadic cases for each familial case. The gender distribution, age and immunoglobulin subtypes of familial cases were unremarkable in comparison to sporadic cases. With a median follow-up of 7.4 years after diagnosis, the percentage of MGUS cases having evolved to MM was 3%. The median overall survival of the 148 familial MM cases was longer than that of matched sporadic cases, with projected values of 7.6 and 16.1 years in patients older and younger than 65 years, respectively. These data suggest that familial cases of monoclonal gammopathy are similar to sporadic cases in terms of clinical presentation and carry a better prognosis.

Identifiants

pubmed: 36588407
doi: 10.1002/ajh.26785
pmc: PMC10107808
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

264-271

Informations de copyright

© 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.

Références

Cancer Causes Control. 1992 Nov;3(6):555-68
pubmed: 1420859
Rev Rhum Engl Ed. 1995 Jun;62(6):439-45
pubmed: 7552209
Nat Genet. 2013 Oct;45(10):1221-1225
pubmed: 23955597
Stat Med. 2014 Mar 30;33(7):1242-58
pubmed: 24122911
Leukemia. 2016 Mar;30(3):627-32
pubmed: 26449663
Br J Haematol. 2015 Apr;169(1):57-70
pubmed: 25521164
J Am Geriatr Soc. 1989 Apr;37(4):303-9
pubmed: 2921451
N Engl J Med. 2008 Jul 10;359(2):152-7
pubmed: 18614782
Blood Adv. 2017 Apr 07;1(10):619-623
pubmed: 29296704
Blood. 2008 Oct 15;112(8):3052-6
pubmed: 18703425
J Natl Cancer Inst. 2005 Oct 5;97(19):1466-74
pubmed: 16204696
Br J Haematol. 1998 Dec;103(3):696-703
pubmed: 9858219
Br J Haematol. 1999 Jun;105(3):768-70
pubmed: 10354144
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
Blood. 2014 Apr 17;123(16):2513-7; quiz 2593
pubmed: 24449210
Cancer. 2004 Dec 1;101(11):2667-74
pubmed: 15481060
Leukemia. 2019 Sep;33(9):2324-2330
pubmed: 30967618
Biomed Res Int. 2013;2013:396272
pubmed: 23555086
Eur J Cancer. 2006 Jul;42(11):1661-70
pubmed: 16753294
Am J Hematol. 2023 Feb;98(2):264-271
pubmed: 36588407
Leukemia. 2014 Mar;28(3):518-24
pubmed: 24247655
Blood. 2009 Jul 23;114(4):785-90
pubmed: 19179466
Cancer Causes Control. 1992 Jan;3(1):63-7
pubmed: 1536915
Nat Commun. 2018 Apr 25;9(1):1649
pubmed: 29695719
J Epidemiol. 2001 Nov;11(6):249-54
pubmed: 11769942
Am J Epidemiol. 2004 Feb 15;159(4):373-80
pubmed: 14769641
Blood. 2015 Mar 26;125(13):2174-5
pubmed: 25814489
Blood Adv. 2020 Jun 23;4(12):2789-2797
pubmed: 32569378
Blood. 2011 Jul 21;118(3):635-7
pubmed: 21586751
Epidemiology. 1993 Sep;4(5):398-406
pubmed: 8399687
Int J Cancer. 2017 Feb 1;140(3):581-590
pubmed: 27759937
Multivariate Behav Res. 2011;46(1):119-151
pubmed: 22287812
Cell Rep. 2017 Sep 12;20(11):2556-2564
pubmed: 28903037
Br J Haematol. 2016 Oct;175(1):87-101
pubmed: 27330041
Clin Lab Haematol. 1998 Jun;20(3):191-3
pubmed: 9681238
J Urol. 2006 Dec;176(6 Pt 1):2438-42; discussion 2442
pubmed: 17085123
Nat Commun. 2016 Jul 01;7:12050
pubmed: 27363682
PLoS One. 2018 May 1;13(5):e0196596
pubmed: 29715281
Nat Commun. 2018 Sep 13;9(1):3707
pubmed: 30213928
Leukemia. 2022 Apr;36(4):1058-1065
pubmed: 34764424
Int J Cancer. 2009 Nov 1;125(9):2147-50
pubmed: 19582882
Am J Hematol. 2009 Jan;84(1):34-8
pubmed: 19037864
Int J Cancer. 2003 Oct 20;107(1):134-8
pubmed: 12925968

Auteurs

Charles Dumontet (C)

Hospices Civils de Lyon, Lyon, France.
CRCL, UMR INSERM 1052/CNRS 5286/University of Lyon-France, Lyon, France.

Delphine Demangel (D)

Hospices Civils de Lyon, Lyon, France.

Perrine Galia (P)

Hospices Civils de Lyon, Lyon, France.

Lionel Karlin (L)

Hospices Civils de Lyon, Lyon, France.

Laurent Roche (L)

Hospices Civils de Lyon, Lyon, France.

Mathieu Fauvernier (M)

Hospices Civils de Lyon, Lyon, France.

Camille Golfier (C)

Hospices Civils de Lyon, Lyon, France.

Marie-Charlotte Laude (MC)

Hospices Civils de Lyon, Lyon, France.

Xavier Leleu (X)

Hematology Department, CHU Poitiers, Poitiers, France.

Philippe Rodon (P)

Hematology Department, CH Périgueux, Périgueux, France.

Murielle Roussel (M)

IUC-Oncopôle, Toulouse, France.

Isabelle Azaïs (I)

Hematology Department, CHU Poitiers, Poitiers, France.

Chantal Doyen (C)

UCL Mont-Godinne, Louvain, Belgium.

Borhane Slama (B)

Clinical Hematology Department, CH Avignon, Avignon, France.

Salomon Manier (S)

Hematology Department, CHRU, Lille, France.

Olivier Decaux (O)

Hematology Department, CHU Rennes, Inserm UMR1236, Rennes, France.

Maroulio Pertesi (M)

Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.
Department of Laboratory Medicine, Hematology and Transfusion Medicine, Lund, Sweden.

Marie Beaumont (M)

Hematology Department, CHU Dunkerque, Dunkerque, France.

Denis Caillot (D)

Clinical Hematology Department, Hôpital F. Mitterrand, CHU Dijon, Dijon, France.

Eileen M Boyle (EM)

Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.

Manuel Cliquennois (M)

Hospitals Organization of Catholic Institute, Lille, France.

Pascale Cony-Makhoul (P)

CH Annecy Genevois, Pringy, France.

Anne-Violaine Doncker (AV)

Private Hospital Sévigné, Cesson-Sévigné, France.

Véronique Dorvaux (V)

Clinical Hematology Department, CHR Metz-Thionville, Metz-Thionville, France.

Marie Odile Petillon (MO)

Intergroupe Francophone du Myélome, France.

Jean Fontan (J)

Hematology Department, CHU Besançon, Besançon, France.

Bénédicte Hivert (B)

Hospitals Organization of Catholic Institute, Lille, France.

Isabelle Leduc (I)

Hematology Department, CH d'Abbeville, Abbeville, France.

Cécile Leyronnas (C)

Daniel Hollard Institute-GHM-Grenoble, Grenoble, France.

Margaret Macro (M)

Hematology Department, CHU Caen, Caen, France.

Michel Maigre (M)

Internal Medicine Department, CH Chartres, Chartres, France.

Clara Mariette (C)

Hematology Department, CHU Grenoble, Grenoble, France.

Philippe Mineur (P)

Clinical Hematology Department, Grand Hôpital de Charleroi, Charleroi, Belgium.

Sophie Rigaudeau (S)

Hematology Department, CH Versailles, Versailles, France.

Bruno Royer (B)

Clinical Hematology and Cell Therapy Department, Amiens, France.

Laure Vincent (L)

Clinical Hematology Department, CHU Montpellier, France.

James Mckay (J)

Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.

Emeline Perrial (E)

CRCL, UMR INSERM 1052/CNRS 5286/University of Lyon-France, Lyon, France.

Laurent Garderet (L)

HU PITIE SALPETRIERE APHP, Paris, France.
Centre de Recherche Saint-Antoine-Team Hematopoietic and Leukemic Development, Sorbonne Université-INSERM, UMR_S 938, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH